What does it take to transform the outlook for patients facing some of the most difficult cancers? Dr. Dietmar Berger, Chief Medical Officer at Gilead
Sciences, shares how the company is tackling urgent needs in triple negative breast cancer (TNBC) and pioneering the next generation of CAR-T therapies to reshape what’s possible in oncology.
 
Read more: <a href="https://www.statnews.com/sponsor/2025/10/09/taking-possibility-back-across-oncologys-toughest-frontiers/">https://www.statnews.com/sponsor/2025/10/09/taking-possibility-back-across-oncologys-toughest-frontiers/</a>
 
Photo: Radhika Patnala/Endosymbiont GmBH

The Nucleus x SBS: How proteomics and multi-omics are deepening our understanding of human health

STAT Brand Studio creates creates custom content that merges the brand identity of our partners with STAT’s mission-driven and journalistic voice. We work with partners to inspire, engage, and inform our influential audience within the life sciences.